DeMulder P - Search Results

1

Osteonecrosis in patients with testicular tumours treated with chemotherapy.

van den Berkmortel F, de Wit R, de Rooy J, DeMulder P. van den Berkmortel F, et al. Among authors: demulder p. Neth J Med. 2004 Jan;62(1):23-7. Neth J Med. 2004. PMID: 15061230 Free article.

2

Optimal control of acute cisplatin-induced emesis.

Verweij J, de Wit R, de Mulder PH. Verweij J, et al. Oncology. 1996 Jun;53 Suppl 1:56-64. doi: 10.1159/000227642. Oncology. 1996. PMID: 8692553 Review.

3

Experience with dose and schedule variations in germ cell tumors.

De Mulder PH, de Wit R. De Mulder PH, et al. Anticancer Drugs. 1995 Oct;6 Suppl 5:43-52. doi: 10.1097/00001813-199510005-00005. Anticancer Drugs. 1995. PMID: 8845494 Review.

4

Treatment in germ cell tumours: state of the art.

Tjan-Heijnen VC, Oosterhof GO, de Wit R, De Mulder PH. Tjan-Heijnen VC, et al. Eur J Surg Oncol. 1997 Apr;23(2):110-7. doi: 10.1016/s0748-7983(97)80002-9. Eur J Surg Oncol. 1997. PMID: 9158183 Review.

5

[A young man with rapidly progressing dyspnoea and a mediastinal mass].

van Spronsen DJ, van den Berkmortel FW, Bootsma GP, de Mulder PH. van Spronsen DJ, et al. Ned Tijdschr Geneeskd. 2004 Nov 13;148(46):2286-9. Ned Tijdschr Geneeskd. 2004. PMID: 15586435 Dutch.

6

Analysis of cumulative probabilities shows that the efficacy of 5HT3 antagonist prophylaxis is not maintained.

de Wit R, Schmitz PI, Verweij J, de Boer-Dennert M, de Mulder PH, Planting AS, van der Burg ME, Stoter G. de Wit R, et al. J Clin Oncol. 1996 Feb;14(2):644-51. doi: 10.1200/JCO.1996.14.2.644. J Clin Oncol. 1996. PMID: 8636782 Free article.

7

Serum alpha-fetoprotein surge after the initiation of chemotherapy for non-seminomatous testicular cancer has an adverse prognostic significance.

de Wit R, Collette L, Sylvester R, de Mulder PH, Sleijfer DT, ten Bokkel Huinink WW, Kaye SB, van Oosterom AT, Boven E, Stoter G. de Wit R, et al. Br J Cancer. 1998 Nov;78(10):1350-5. doi: 10.1038/bjc.1998.683. Br J Cancer. 1998. PMID: 9823978 Free PMC article.

8

Management of intermediate-prognosis germ-cell cancer: results of a phase I/II study of Taxol-BEP.

de Wit R, Louwerens M, de Mulder PH, Verweij J, Rodenhuis S, Schornagel J. de Wit R, et al. Int J Cancer. 1999 Dec 10;83(6):831-3. doi: 10.1002/(sici)1097-0215(19991210)83:6<831::aid-ijc24>3.0.co;2-o. Int J Cancer. 1999. PMID: 10597204 Clinical Trial.

9

A multi-center prospective phase II study of high-dose chemotherapy in germ-cell cancer patients relapsing from complete remission.

Rodenhuis S, de Wit R, de Mulder PH, Keizer HJ, Sleijfer DT, Lalisang RI, Bakker PJ, Mandjes I, Kooi M, de Vries EG. Rodenhuis S, et al. Ann Oncol. 1999 Dec;10(12):1467-73. doi: 10.1023/a:1008328012040. Ann Oncol. 1999. PMID: 10643538 Free article. Clinical Trial.

10

Intensive induction chemotherapy with C-BOP/BEP for intermediate- and poor-risk metastatic germ cell tumours (EORTC trial 30948).

Fosså SD, Paluchowska B, Horwich A, Kaiser G, de Mulder PH, Koriakine O, van Oosterom AT, de Prijck L, Collette L, de Wit R; EORTC GU Group. Fosså SD, et al. Br J Cancer. 2005 Nov 28;93(11):1209-14. doi: 10.1038/sj.bjc.6602830. Br J Cancer. 2005. PMID: 16251877 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

210 results

Search Page

Filters